Howard J, Beckwith L
Department of Pediatrics, University of California, Los Angeles School of Medicine 90095-7033, USA.
NIDA Res Monogr. 1996;166:68-86.
To advance knowledge about the treatment of addiction among pregnant women and other women of childbearing age, investigators must adhere to the requirements of a strict experimental research design while concurrently providing clinical services. This means that researchers must address a variety of difficult questions, including the following: Was the sample large enough? Were the criteria for subject inclusion and exclusion well defined? Did the process of recruitment result in a sample that could be generalized to a larger population, or was the sample biased in some way? Was assignment to groups clearly random? What was the attrition rate? Was attrition the same in both experimental and comparison groups? Did baseline measures collect enough information to permit a description of the facts that were associated with attrition in each group? Was the attrition rate so high that the retained sample had special characteristics? If so, what were these features? This chapter highlights several problems related to these questions, describes the difficulties that investigators have faced in meeting clinical and research challenges to date, and suggests strategies for overcoming some obstacles. In establishing the Perinatal-20 project, the National Institute on Drug Abuse took an informed first step in organizing a substantial research effort to investigate treatment modalities that incorporate services specific to the needs of substance-abusing women who have children. This initial effort has resulted in a beginning knowledge base that can be used to refine and expand future treatment efforts. Even the issue of the "study unit" for this population is evolving. Today's researchers are attempting to determine whether the mother alone or the mother along with her dependent children constitutes the study unit. This question also has led professionals in the field to examine a range of specific outcome priorities, and investigators just now are beginning to determine exactly what needs to be evaluated in gauging the effectiveness of treatment. Is success measured on the basis of the woman's progress with abstinence alone, or does it also include her role with her children? Is it determined on the basis of her relationship with her children or the children's growth and development? Compared with providing services for and studying single adult subjects, developing treatment for women and their children presents researchers with a more complex task and requires expanded clinical services (Gallagher 1990, pp. 540-559). As in most fields of study, initial research data in substance abuse treatment for pregnant and parenting women are derived from samples of convenience, as described above. To put this information in perspective, future research will require a wider and more representative spectrum of the population. Furthermore, tensions between clinical needs and research requirements must be considered in advance, and methods for relaxing these tensions will be critical to the success of future efforts. For example, members of both the research and clinical staff teams must be absolutely clear about the study design and the requirements of reliable research. Where possible, potential ambiguities about group assignment, project services, subjects' responsibilities, and so forth must be incorporated into subject consent forms so that the subjects also are apprised of potential problems and their solutions. A final caution to future investigators is to be aware of the economic, physical, and personnel limitations of the range of treatment services that can be provided in a research demonstration study involving this population. Because of these limitations and the extensive range of services the subjects of the studies require, treatment components must be discrete and carefully defined to prevent programs from becoming impractically diverse and unclear. Research goals must be attainable and measurable.(ABSTRACT TRUNCATED)
为了增进对孕妇及其他育龄期女性成瘾治疗的了解,研究人员在提供临床服务的同时,必须遵循严格的实验研究设计要求。这意味着研究人员必须解决各种难题,包括以下这些:样本量足够大吗?纳入和排除受试者的标准是否明确界定?招募过程所得到的样本能够推广至更广泛的人群,还是在某些方面存在偏差?分组是否明确随机?损耗率是多少?实验组和对照组的损耗率相同吗?基线测量是否收集了足够的信息,以便描述与每组损耗相关的事实?损耗率是否过高,以至于留存样本具有特殊特征?如果是,这些特征是什么?本章着重介绍了与这些问题相关的若干难题,描述了研究人员迄今为止在应对临床和研究挑战时所面临的困难,并提出了克服一些障碍的策略。在设立围产期 - 20 项目时,国家药物滥用研究所迈出了明智的第一步,组织了一项大规模研究工作,以调查针对有子女的药物滥用女性的特定需求而提供服务的治疗模式。这一初步努力已形成了一个初始知识库,可用于完善和扩大未来的治疗工作。甚至针对这一人群的“研究单位”问题也在不断演变。如今的研究人员正试图确定研究单位是仅母亲一人,还是母亲及其受抚养子女。这个问题也促使该领域的专业人员审视一系列具体的结果优先事项,而研究人员刚刚开始确定在评估治疗效果时究竟需要评估哪些内容。成功的衡量标准仅仅是基于女性在戒除方面的进展,还是也包括她与子女的关系?是根据她与子女的关系来确定,还是依据子女的成长和发展来确定?与为单身成年受试者提供服务和开展研究相比,为女性及其子女开发治疗方法给研究人员带来了更复杂的任务,并且需要扩大临床服务范围(加拉格尔,1990 年,第 540 - 559 页)。与大多数研究领域一样,针对怀孕和育有子女女性的药物滥用治疗的初步研究数据来自于方便样本,如上文所述。从全面的角度看待这些信息,未来的研究将需要更广泛且更具代表性的人群样本。此外,必须提前考虑临床需求与研究要求之间的矛盾,缓解这些矛盾的方法对于未来工作的成功至关重要。例如,研究和临床工作人员团队的成员必须对研究设计以及可靠研究的要求有绝对清晰的认识。在可能情况下,关于分组、项目服务、受试者责任等方面的潜在模糊之处必须纳入受试者同意书中,以便受试者也了解潜在问题及其解决方案。对未来研究人员的最后一个提醒是,要意识到在涉及这一人群的研究示范项目中能够提供的治疗服务范围在经济、物力和人力方面的限制。由于这些限制以及研究受试者所需的广泛服务范围,治疗组成部分必须是离散且经过仔细界定的,以防止项目变得过于多样化且不明确而难以实施。研究目标必须是可实现且可衡量的。(摘要截选)